Other languages IGM Biosciences, Inc.

Equities

IGMS

US4495851085

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
7.65 ^USD	-3.89%		+3.24%	-7.94%

Apr. 17	IGM Biosciences, Sanofi Narrow Partnership to Focus on Potential Immunology and Inflamation Targets	MT
Apr. 17	IGM Biosciences, Inc. Announces Refocusing of Sanofi Collaboration	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

IGM Biosciences, Inc. Announces Refocusing of Sanofi Collaboration	Apr. 17
IGM Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 07
IGM Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 07
IGM Biosciences to Reduce Workforce by 22%, Pause Hematologic Oncology Clinical Development	Dec. 06
MORNING BRIEFING - USA/Asien	Dec. 06
Igm Biosciences, Inc. to Reduce its Workforce by Approximately 22%	Dec. 05
IGM Biosciences, Inc. Announces Plans to File IND for IGM-2644 (CD38 x CD3) to Treat Autoimmune Disease	Dec. 05
IGM Biosciences Q3 Loss Narrows, Collaboration Revenue Rises; Shares Fall After Hours	Nov. 13
IGM Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13
IGM Biosciences, Inc. Announces Board Changes	23-10-03
IGM Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03
IGM Biosciences Plans $100 Million Public Stock Offering, Concurrent Private Placement of Securities; Shares Fall	23-06-21
IGM Biosciences, Inc. Announces Update on IGM-8444 Phase 1 Trial and Future Clinical Development	23-06-21
IGM Biosciences, Inc. Announces FDA Clearance to Begin Clinical Studies of Imvotamab in Lupus and Rheumatoid Arthritis	23-05-31
IGM Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12
IGM Biosciences Q4 Net Loss Narrows	23-03-30
IGM Biosciences Says First Patient Dosed in Trial for Potential Solid Tumor Treatment	23-01-17
IGM Biosciences Initiates First-In-Human Clinical Trial of Igm-7354 in Solid Tumors	23-01-17
IGM Biosciences Announces Update on Igm-8444 Phase 1 Trial and Future Clinical Development	23-01-09
Insider Buy: Igm Biosciences	22-11-10

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages IGM Biosciences, Inc.

Equities

IGMS

US4495851085

Other languages

Filters